Immunovant Inc
IMVT
NASDAQ
Biotechnology
$41.82
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.62B
Volume 722.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-505.61M
TTM
-22.2%
YoY
Operating Cash Flow
$-407.31M
TTM
-8.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 20.2 | 26.0 | 17.5 | 15.4 | 17.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 113.8 | 127.2 | 131.8 | 114.4 | 159.6 |
Operating Income | -113.8 | -127.2 | -131.8 | -114.4 | -159.6 |
EBITDA | -113.7 | -127.1 | -131.7 | -114.3 | -159.5 |
Other Income / Expense | 1.1 | 1.2 | 0.3 | -0.1 | 0.8 |
Total Other Income / Expense | 8.0 | 7.5 | 5.9 | 5.3 | 8.9 |
Income Before Income Taxes | -105.9 | -119.7 | -125.9 | -109.1 | -150.7 |
Income Taxes | 0.6 | 0.9 | 0.6 | 1.6 | -2.8 |
Net Income | -106.4 | -120.6 | -126.5 | -110.6 | -147.9 |
Consolidated Net Income / Loss | -106.4 | -120.6 | -126.5 | -110.6 | -147.9 |
Net Income Attributable to Common Shareholders | -106.4 | -120.6 | -126.5 | -110.6 | -147.9 |
Basic EPS | -$0.64 | -$0.71 | -$0.73 | -$0.61 | -$0.73 |
Diluted EPS | -$0.64 | -$0.71 | -$0.73 | -$0.61 | -$0.73 |
Basic Shares Outstanding | 166.8M | 170.9M | 173.6M | 181.5M | 203.7M |
Diluted Shares Outstanding | 166.8M | 170.9M | 173.6M | 181.5M | 203.7M |